Gülden Paçacı Çetin

Gülden Paçacı Çetin

Auto-generated profile, based on publicly available information

Gülden Paçacı Çetin

Department of Chest Diseases, Division of Allergy and Immunology, Erciyes University, School of Medicine

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2023 in Journal of Asthma
Verified
Journal Article
Closed access
GCGulfem Elif Celik
Gulfem Elif Celik
OAOmur Aydin
Omur Aydin
DGDerya Gökmen
Derya Gökmen
GBGozde Koycu Buhari
Gozde Koycu Buhari
ZSZeynep Celebi Sözener
Zeynep Celebi Sözener
AYArzu Yorgancioglu
Arzu Yorgancioglu
National data on asthma characteristics and the factors associated with uncontrolled asthma seem to be necessary for every country. For this purpose, we developed the Turkish Adult Asthma Registry ...

2 August 2022 in International Archives of Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
BABahar Arslan
Bahar Arslan
GÇGülden Paçacı Çetin
Gülden Paçacı Çetin
MTMurat Türk
Murat Türk
IGİnCi Gülmez
İnCi Gülmez
IYİnSu Yılmaz
İnSu Yılmaz
Background: Although there are many studies presenting the efficacy of omalizumab in severe asthma, the data about the optimal treatment duration are still debated. Objective: In this study, we aimed to investigate the clinical effects of omalizumab discontinuation after 5 years of treatment in patients with omalizumab super-responders, the persistence of response and to compare the features of patients, whose symptoms are still well controlled and those who relapsed and re-treated with omalizumab. Methods: Clinical and laboratory data of 100 adult patients diagnosed with allergic severe asthma and treated with omalizumab between 2008 and 2020 were evaluated retrospectively. Demographic, clinical, functional, and laboratory parameters of the patients who were re-treated with omalizumab and those who did not need to be re-treated were compared. Results: There were 14 super-responder patients, who were treated with omalizumab for 5 years, and the treatment was discontinued then. Omalizumab was not restarted in 9 patients (64%) and was restarted in 5 (36%) patients. No significant difference was presented between these two groups in terms of demographic, clinical, functional, and laboratory parameters. The baseline total IgE levels of patients, who were re-treated with omalizumab, was found to be higher than those who were not, but this difference was not statistically significant (440 [229–864] IU/mL vs. 164 [85–293] IU/mL; p = 0.053, respectively). Conclusion: One of 3 patients was re-treated with omalizumab due to loss of asthma control after discontinuation of the treatment. Therefore, omalizumab’s immunomodulatory effect may seem to persist in a majority of cases after discontinuation. Also, higher baseline total IgE levels might help to predict the cases that need re-treatment after discontinuation.

10 March 2023 in Tuberk Toraks
Verified
Journal Article
Open access
IYİnSu Yılmaz
İnSu Yılmaz
GÇGülden Paçacı Çetin
Gülden Paçacı Çetin
BABahar Arslan
Bahar Arslan
SŞSerhat Şeker
Serhat Şeker
HYHatice Eylül Bozkurt Yılmaz
Hatice Eylül Bozkurt Yılmaz
EAElif Açar
Elif Açar
The aim of this review is to elaborate the management of biologic therapy from initial selection to switching biologics in severe asthma. A nonsystematic review was performed for biological therapy management in severe asthma. Depending on clinical characteristics and biomarkers, selecting the preferred biologic based on super-responder criteria from previous studies may result in adequate clinical efficacy in most patients. On the other hand, no matter how carefully the choice is made, in some patients, it may be necessary to discontinue the drug due to suboptimal clinical response or even no response. This may result in the need to switch to a different biological therapy. How long the biological treatment of patients whose asthma is controlled with biologics will be continued and according to which criteria they will be terminated remains unclear. It has been shown that in patients with a long history of good response to biologics, asthma control may be impaired when biologics are discontinued, while it may persist in others. Therefore, discontinuation of biologics may be a viable strategy in a particular patient group. Clinicians should make the best use of all predictive factors to identify patients who will most benefit from each biologic. Patients who do not meet a predefined response criterion after sufficient time for response evaluation and who are eligible for one or more alternative biological agents should be offered the opportunity to switch to another biologic. There is no consensus on when the biologics used in severe asthma that produce favorable results should be discontinued. In our opinion, treatment should continue for at least five years, as premature termination may potentially deteriorate asthma control.

1 August 2023 in Journal of Aerosol Medicine and Pulmonary Drug Delivery
Verified
Journal Article
Closed access
BABahar Arslan
Bahar Arslan
GÇGülden Paçacı Çetin
Gülden Paçacı Çetin
IYİnSu Yilmaz
İnSu Yilmaz
The journey of using anticholinergics in the treatment of asthma started with anticholinergic-containing plants such as Datura stramonium and Atropa belladonna, followed by ipratropium bromide and continued with tiotropium, glycopyrronium, and umeclidinium. Although antimuscarinics were used in the maintenance treatment of asthma over a century ago, after a long time (since 2014), it has been recommended to be used as an add-on long-acting antimuscarinic agent (LAMA) therapy in the maintenance treatment of asthma. The airway tone controlled by the vagus nerve is increased in asthma. Allergens, toxins, or viruses cause airway inflammation and inflammation-related epithelial damage, increased sensory nerve stimulation, ganglionic and postganglionic acetylcholine (ACh) release by inflammatory mediators, intensification of ACh signaling at M1 and M3 muscarinic ACh receptors (mAChRs), and dysfunction of M2 mAChR. Optimal anticholinergic drug for asthma should effectively block M3 and M1 receptors, but have minimal effect on M2 receptors. Tiotropium, umeclidinium, and glycopyrronium are anticholinergic agents with this feature. Tiotropium has been used in a separate inhaler as an add-on treatment to inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA), and glycopyrronium and umeclidinium have been used in a single inhaler as a combination of ICS/LABA/LAMA in asthma in recent years. Guidelines recommend this regimen as an optimization step for patients with severe asthma before initiating any biologic or systemic corticosteroid therapy. In this review, the history of antimuscarinic agents, their effectiveness and safety in line with randomized controlled trials, and real-life studies in asthma treatment will be discussed according to the current data.

30 August 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
IYİnSu Yilmaz
İnSu Yilmaz
SBSakine Nazi̇k Bahçeci̇oĞlu
Sakine Nazi̇k Bahçeci̇oĞlu
MTMurat Türk
Murat Türk
NTNuri Tutar
Nuri Tutar
GÇGülden Paçaci Çeti̇n
Gülden Paçaci Çeti̇n
BABahar Arslan
Bahar Arslan
Background: The efficacy of mepolizumab has been largely demonstrated in clinical trials in patients with severe eosinophilic asthma (SEA). However, reports on experience with mepolizumab in a real-life cohort are limited. Moreover, data about the effectiveness of mepolizumab on small airways is scarce. Objective: This study evaluated the effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, blood eosinophils, steroid dependence and small airways in a real-life cohort of patients with SEA. Materials and methods: We retrospectively analyzed patients with SEA who were receiving fixed-dose mepolizumab. The effects of mepolizumab on clinical, laboratory, functional parameters were evaluated at 12th, 24th, 52nd weeks. Small airways were assessed with the FEF 25-75. Results: A total of 41 patients were enrolled in the study. Mepolizumab significantly reduced asthma exacerbation rates, reduced mOCS dose, and improved asthma control test (ACT) scores at 12th, 24th and 52nd weeks. However, we found no significant changes in FEV1 and FEF 25-75 values at baseline, 12th, 24th and 52nd weeks (78.9 +/- 23.3%, 82.9 +/- 23.4%, 81.9 +/- 23.9% and 78.9 +/- 23.5% for FEV1; 45.1 +/- 23.1%, 48.8 +/- 23.5%, 48.7 +/- 23.1% and 41.0 +/- 20.1% for FEF 25-75, respectively) Conclusion: In this study, mepolizumab significantly improved all outcomes (symptom scores, asthma exacerbations, OCS sparing and blood eosinophils) except functional parameters. Still, despite the dose reduction in mOCS dosage, no significant deterioration was observed in FEV1 and FEF25-75 values

16 February 2025 in Journal of Asthma
Verified
Journal Article
Closed access
ZSZeynep Celebi Sözener
Zeynep Celebi Sözener
IOI.Kivilcim Oguzulgen
I.Kivilcim Oguzulgen
FAFunda Seher Ozalp Ates
Funda Seher Ozalp Ates
ABAyse Baccioglu
Ayse Baccioglu
SBSerap Argun Baris
Serap Argun Baris
GCGulfem Elif Celik
Gulfem Elif Celik
The obese-asthma phenotype has gradually increased in the last few years. We aimed to assess the differences between obese and non-obese patients with asthma. This research is a subanalysis of the Turkish Adult Asthma Registry (TAAR). Clinical presentation, disease control, severity, and demographics of obese and non-obese (lean, normal-weight, overweight) patients were compared. The obesity rate in TAAR was 32.2% (n = 619/1919; 18-83 years; 527 F/92 M). Patients with asthma and obesity had higher rates of childhood obesity, longer symptom duration, later onset of asthma, and more severe asthma. These patients were more likely to be female, older, less educated, and live in rural areas. Patients with obesity had more scheduled visits and emergency visits compared with non-obese patients, but similar asthma control, oral corticosteroid use, hospitalizations, intensive care unit admissions, and unscheduled visits. They also had a higher frequency of T2-high but lower frequency of possible T2-low phenotypes compared with normal-weight asthmatics. The risk of severe asthma in patients with obesity was 6.04 times higher for allergic than non-allergic patients and 3.58 times higher for the T2-high phenotype than for possible T2-low phenotypes. A one-unit increase in the asthma control test reduced the risk of severe asthma by 22%. A good definition of this phenotype is important to ensure that appropriate treatment strategies are implemented to achieve the control goal. We also believe that prevention of childhood obesity is an effective and pivotal strategy to achieve the goal of asthma control.